Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up |
| |
| Authors: | F W Willem Den Otter Graham Hill Wim R Klein Jan Willem Koten Peter A Steerenberg Pieter H M De Mulder Christopher Rhode Rachel Stewart Joop A J Faber E Joost Ruitenberg Victor P M G Rutten |
| |
| Institution: | (1) Department of Functional Morphology, Faculty of Veterinary Medicine, PO Box 80.157, 3508 TD Utrecht, The Netherlands;(2) Faculty of Veterinary Science, University of Zimbabwe, P. O. Box MP 167, Harare, Zimbabwe;(3) Department of General Surgery and Large Animal Surgery, Faculty of Veterinary Medicine, Yalelaan 12, Utrecht, The Netherlands;(4) Department of Immunology, Faculty of Veterinary Medicine, Institute of Infectious Diseases and Immunology, Yalelaan 1, Utrecht, The Netherlands;(5) Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, Amsterdam, The Netherlands;(6) Laboratory of Pathology, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands;(7) Department of Medicine, Division of Medical Oncology, University of Nijmegen, The Netherlands;(8) Center for Biostatistics, Padualaan 4, Utrecht, The Netherlands |
| |
| Abstract: | We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2(IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1–3 cm in diameter, were treated with 5000, 20 000 or 200 000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20 000 U and 67% treated with 200 000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9-and 20-month results of the 200 000-U treatment are significantly better than those of the 5000-U and 20 000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients. |
| |
| Keywords: | IL-2 therapy Cancer Immunotherapy Bovine ocular squamous-cell carcinoma |
| 本文献已被 SpringerLink 等数据库收录！ |
|
